Mineralys Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Its last 6 Sell calls were actually followed by a +37% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -57.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -36.9% | Better than 11% |
| Return on invested capital | -40.7% | Better than 7% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -46.7% | Better than 7% |
| 6-month return | -54.2% | Better than 6% |
| 12-month return (ex latest month) | -50.9% | Better than 3% |
| Distance below 52-week high | 69.0% | Better than 6% |
Financial Health D+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 43.8x | Better than 100% |
| Debt to assets | 302.8% | Better than 0% |
| Interest coverage | -717.8x | Better than 2% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 233.1% | Better than 96% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 14.16
- Open
- 13.81
- Day range
- 13.57 - 14.79
- Avg price
- 13.86
- Volume
- 1.35M
- Turnover
- 18.65M
- Turnover ratei
- 2.02%
- Volume ratioi
- 1.12
- Amplitudei
- 8.62%
- 52-week rangei
- 13.57 - 44.13
Valuation
- P/Ei
- -5.97
- P/E (TTM)i
- -3.18
- P/Bi
- 2.40
- EPSi
- -2.29
- Book value / shi
- 5.69
- Net profit
- -202.80M
- Net assets
- 503.80M
Share structure
- Market cap
- 1.21B
- Float capi
- 911.75M
- Shares out
- 88.56M
- Float sharesi
- 66.75M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2023-02-10
69.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-10.90M net over the window
Short interest
- Shares short
- 7.69M
- % of floati
- 8.70%
- Days to coveri
- 4.95
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics last traded at 13.66. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Mineralys Therapeutics's market cap?
About 1.21B.
What is the P/E ratio of Mineralys Therapeutics?
The trailing twelve-month P/E is -3.18. The Valuation tab shows it against the stock's own five-year range.
Does Mineralys Therapeutics pay a dividend?
Mineralys Therapeutics does not currently pay a regular dividend.
Is Mineralys Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 45.50, which implies 233.1% upside from the current price. This is not investment advice.
What is Mineralys Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Mineralys Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mineralys Therapeutics discussion 0 comments